PL3890781T3 - Inhibitor punktów kontrolnych odpowiedzi układu odpornościowego w połączeniu z terapią sonodynamiczną - Google Patents
Inhibitor punktów kontrolnych odpowiedzi układu odpornościowego w połączeniu z terapią sonodynamicznąInfo
- Publication number
- PL3890781T3 PL3890781T3 PL19820858.9T PL19820858T PL3890781T3 PL 3890781 T3 PL3890781 T3 PL 3890781T3 PL 19820858 T PL19820858 T PL 19820858T PL 3890781 T3 PL3890781 T3 PL 3890781T3
- Authority
- PL
- Poland
- Prior art keywords
- combination
- immune checkpoint
- checkpoint inhibitor
- sonodynamic therapy
- sonodynamic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1819853.1A GB201819853D0 (en) | 2018-12-05 | 2018-12-05 | Therapy |
| PCT/GB2019/053441 WO2020115491A2 (en) | 2018-12-05 | 2019-12-05 | Therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3890781T3 true PL3890781T3 (pl) | 2026-03-23 |
Family
ID=65030185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19820858.9T PL3890781T3 (pl) | 2018-12-05 | 2019-12-05 | Inhibitor punktów kontrolnych odpowiedzi układu odpornościowego w połączeniu z terapią sonodynamiczną |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220062417A1 (pl) |
| EP (1) | EP3890781B1 (pl) |
| ES (1) | ES3057007T3 (pl) |
| GB (1) | GB201819853D0 (pl) |
| PL (1) | PL3890781T3 (pl) |
| WO (1) | WO2020115491A2 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160243234A1 (en) | 2013-09-27 | 2016-08-25 | Phoenix Solutions As | Ultrasound mediated delivery of drugs |
| JP2022521831A (ja) * | 2019-03-29 | 2022-04-12 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 標的指向性協働的がん免疫療法 |
| KR102379296B1 (ko) * | 2019-09-02 | 2022-03-29 | (주)아이엠지티 | 면역 마이크로버블 복합체 및 이의 이용 |
| KR102578025B1 (ko) * | 2020-12-07 | 2023-09-15 | (주)아이엠지티 | 초음파 감작제가 결합된 면역관문억제제 및 이의 용도 |
| GB2629999B (en) * | 2021-04-21 | 2025-03-26 | Act Therapeutics Ltd | Enhancement of treatment with immunotherapeutic agents |
| CN114588268B (zh) * | 2022-03-25 | 2023-05-26 | 清华大学 | 提高激活sting通路和抗肿瘤t细胞应答的方法 |
| NO20221187A1 (en) | 2022-11-04 | 2024-05-06 | Exact Therapeutics As | Method and system for calculating a point estimate of an ultrasound dose |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012122444A1 (en) * | 2011-03-10 | 2012-09-13 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| GB201106803D0 (en) * | 2011-04-21 | 2011-06-01 | Univ Ulster | Sonodynamic therapy |
| US8748446B2 (en) | 2012-03-03 | 2014-06-10 | Nanoquantum Sciences, Inc. | Halogenated compounds for photodynamic therapy |
| WO2015181343A2 (en) * | 2014-05-30 | 2015-12-03 | Ventana Medical Systems, Inc. | Multiplex assay for improved scoring of tumor tissues stained for pd-l1 |
| WO2016061256A1 (en) * | 2014-10-14 | 2016-04-21 | The University Of Chicago | Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof |
| AU2016293674B2 (en) * | 2015-07-16 | 2019-11-21 | Bioxcel Therapeutics, Inc. | A novel approach for treatment of cancer using immunomodulation |
| GB201520649D0 (en) | 2015-11-23 | 2016-01-06 | Univ Ulster | Sonodynamic therapy |
| GB201708663D0 (en) * | 2017-05-31 | 2017-07-12 | Univ Ulster | Therapy |
-
2018
- 2018-12-05 GB GBGB1819853.1A patent/GB201819853D0/en not_active Ceased
-
2019
- 2019-12-05 PL PL19820858.9T patent/PL3890781T3/pl unknown
- 2019-12-05 US US17/299,057 patent/US20220062417A1/en active Pending
- 2019-12-05 ES ES19820858T patent/ES3057007T3/es active Active
- 2019-12-05 EP EP19820858.9A patent/EP3890781B1/en active Active
- 2019-12-05 WO PCT/GB2019/053441 patent/WO2020115491A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES3057007T3 (en) | 2026-02-25 |
| GB201819853D0 (en) | 2019-01-23 |
| EP3890781C0 (en) | 2025-10-08 |
| EP3890781A2 (en) | 2021-10-13 |
| EP3890781B1 (en) | 2025-10-08 |
| US20220062417A1 (en) | 2022-03-03 |
| WO2020115491A2 (en) | 2020-06-11 |
| WO2020115491A3 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286282A (en) | Use of palinabolin in combination with immune checkpoint inhibitors | |
| PL3890781T3 (pl) | Inhibitor punktów kontrolnych odpowiedzi układu odpornościowego w połączeniu z terapią sonodynamiczną | |
| IL265274A (en) | Combined treatment of antibody and checkpoint inhibitor | |
| HUE043847T2 (hu) | Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia | |
| HUE070659T2 (hu) | KDM1A inhibitor és annak felhasználása terápiában | |
| SG10202005298RA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| IL292219A (en) | Immune modulatory il-2 factors in combination with immune checkpoint inhibitors | |
| IL258500A (en) | Combination therapy with glutaminase inhibitors and immuno-oncology agents | |
| HUE065176T2 (hu) | Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében | |
| ZA201804223B (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| IL284053A (en) | New compounds and their use in therapy | |
| SMT202200135T1 (it) | Terapia di combinazione con un inibitore di proteine a bromodomini ed extraterminali | |
| IL273092A (en) | HDAC suppressor in combination with immune checkpoint modulators for cancer treatment | |
| GB201507721D0 (en) | Immunosuppressive agents and their use in therapy | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| PL3157548T3 (pl) | Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| GB201615844D0 (en) | Agents for use in therapy | |
| GB2575123B (en) | Improvements in fasteners | |
| HK40033868A (en) | Hdac inhibitor in combination with immune checkpoint modulator for cancer therapy | |
| GB201800136D0 (en) | Improvements in fasteners | |
| HK1262072A1 (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| AU2016903724A0 (en) | Antibody and checkpoint inhibitor combination therapy | |
| GB201617451D0 (en) | Polypeptides for use in therapy | |
| GB201506127D0 (en) | Immune checkpoint inhibitor combinations |